ANTIVIRAL THERAPY

metrics 2024

Shaping the future of viral disease treatment.

Introduction

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Metrics 2024

SCIMAGO Journal Rank0.45
Journal Impact Factor1.30
Journal Impact Factor (5 years)1.50
H-Index93
Journal IF Without Self1.30
Eigen Factor0.00
Normal Eigen Factor0.20
Influence0.45
Immediacy Index0.60
Cited Half Life11.10
Citing Half Life6.60
JCI0.22
Total Documents2366
WOS Total Citations1736
SCIMAGO Total Citations22134
SCIMAGO SELF Citations1137
Scopus Journal Rank0.45
Cites / Document (2 Years)1.45
Cites / Document (3 Years)1.47
Cites / Document (4 Years)1.41

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #165/272
Percentile 39.34
Quartile Q3
Infectious Diseases in Medicine
Rank #211/344
Percentile 38.66
Quartile Q3
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #219/313
Percentile 30.03
Quartile Q3

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 112/132
Percentile 15.50
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 283/354
Percentile 20.20
Quartile Q4
VIROLOGY
Rank 37/41
Percentile 11.00
Quartile Q4

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 116/132
Percentile 12.12
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 309/354
Percentile 12.71
Quartile Q4
VIROLOGY
Rank 39/41
Percentile 4.88
Quartile Q4

Quartile History

Similar Journals

INTERVIROLOGY

Pioneering insights for a viral-free future.
Publisher: KARGERISSN: 0300-5526Frequency: 6 issues/year

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

Journal of Virus Eradication

Advancing the fight against viral threats.
Publisher: MEDISCRIPT LTDISSN: 2055-6640Frequency: 4 issues/year

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

AIDS RESEARCH AND HUMAN RETROVIRUSES

Fostering Collaboration in Retroviral Science
Publisher: MARY ANN LIEBERT, INCISSN: 0889-2229Frequency: 12 issues/year

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

Journal of Virology

Innovating Solutions for Viral Challenges
Publisher: AMER SOC MICROBIOLOGYISSN: 0022-538XFrequency: 12 issues/year

Journal of Virology is a premier scholarly journal dedicated to advancing the field of virology, focusing on the molecular mechanisms of virus-host interactions, viral pathogenesis, and the latest therapeutic and vaccine developments. Published by the American Society for Microbiology, this esteemed journal has been a cornerstone for researchers since its inception in 1967, providing a platform for high-quality, peer-reviewed research. With a commendable impact factor indicative of its relevance and influence, the journal is categorized in the top quartile (Q1) for Virology, Microbiology, and Insect Science, reflecting its significance in these fields. Researchers can access a wealth of studies and findings that shape our understanding of viruses and their interactions with hosts, highlighting its role in both basic and applied sciences. Positioned in the United States, the Journal of Virology serves a global audience, ensuring that cutting-edge discoveries reach professionals, students, and academics alike. Join the conversation as we explore the complexities of virology and its implications for human health and disease.

Advances in Virology

Connecting Researchers, Elevating Virology
Publisher: HINDAWI LTDISSN: 1687-8639Frequency: 1 issue/year

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

JOURNAL DE MYCOLOGIE MEDICALE

Unveiling Insights into Mycological Challenges
Publisher: MASSON EDITEURISSN: 1156-5233Frequency: 4 issues/year

JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.

Influenza and Other Respiratory Viruses

Advancing knowledge in respiratory viral research.
Publisher: WILEYISSN: 1750-2640Frequency: 6 issues/year

Influenza and Other Respiratory Viruses, published by WILEY, serves as a prominent peer-reviewed platform for the dissemination of research contributing to the understanding and management of respiratory viral infections. With an impressive impact factor and established as an Open Access journal since 2014, it ensures maximum visibility and accessibility of pivotal research findings in the realm of Epidemiology, Infectious Diseases, Public Health, and Pulmonary and Respiratory Medicine. Registered under the ISSN 1750-2640 and E-ISSN 1750-2659, the journal boasts Q1 rankings in four critical categories as of 2023, underscoring its significance within the scientific community. Researchers, professionals, and students can benefit from the convergence of knowledge that this journal facilitates from 2007 to 2024, fostering advancements in understanding viral pathogens and innovative treatment strategies that are increasingly vital to public health efforts globally.

Microbiology Spectrum

Bridging disciplines in the realm of microbiological studies.
Publisher: AMER SOC MICROBIOLOGYISSN: 2165-0497Frequency: 6 issues/year

Microbiology Spectrum is a prominent peer-reviewed journal published by the American Society for Microbiology, dedicated to advancing the field of microbiology through the dissemination of high-quality research. Since its inception in 2013 and continuing until 2024, the journal has established a strong presence in key domains such as microbiology, immunology, cell biology, and ecology, achieving impressive quartile rankings including Q1 in Infectious Diseases and Q1 in Immunology and Microbiology as of 2023. With an emphasis on open access to its scholarly content, Microbiology Spectrum aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike. The journal's scope encompasses a diverse range of topics pertinent to the field, making it an essential resource for anyone involved in microbiological research and its applications. Researchers looking to publish their findings in a respected journal will find Microbiology Spectrum's robust impact factor and Scopus rankings serve as testament to its significance and influence within the academic community.

Infectious Diseases and Therapy

Connecting researchers for a disease-free future.
Publisher: SPRINGER LONDON LTDISSN: 2193-8229Frequency: 4 issues/year

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

JOURNAL OF CLINICAL VIROLOGY

Pioneering Innovative Solutions in Virology
Publisher: ELSEVIERISSN: 1386-6532Frequency: 12 issues/year

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.